50% or greater reduction in seizure frequency · people (aged 12 years and over) with drug‐resistant focal epilepsy
Perampanel add‐on leads to higher ≥ 50% reduction in seizure frequency compared with placebo (high certainty).
1 finding from 1 review
Seizure freedom · people (aged 12 years and over) with drug‐resistant focal epilepsy
Perampanel add‐on may leads to higher seizure freedom compared with placebo (low certainty).
1 finding from 1 review
Acceptability ‐ total dropouts · people (aged 12 years and over) with drug‐resistant focal epilepsy
Perampanel add‐on may leads to higher treatment withdrawal due to any reason compared with placebo (low certainty).
1 finding from 1 review
Withdrawals due to adverse events · people (aged 12 years and over) with drug‐resistant focal epilepsy
Perampanel add‐on may leads to higher treatment withdrawal due to adverse effects compared with placebo (low certainty).
1 finding from 1 review
Proportion of participants who experienced ≥ 1 adverse effect · people (aged 12 years and over) with drug‐resistant focal epilepsy
Perampanel add‐on leads to higher proportion of participants who experienced ≥ 1 adverse effect compared with placebo (high certainty).
1 finding from 1 review
Proportion of participants who experienced ataxia · people (aged 12 years and over) with drug‐resistant focal epilepsy
Perampanel add‐on may leads to higher proportion of participants who experienced ataxia compared with placebo (low certainty).
1 finding from 1 review
Dizziness · people (aged 12 years and over) with drug‐resistant focal epilepsy
Perampanel add‐on may leads to higher proportion of participants who experienced dizziness compared with placebo (low certainty).
1 finding from 1 review